Nextcure Inc (NXTC) Stock Price, Quote & News - Mboum

Company Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease;...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 399 4900

Website: www.nextcure.com

Address:

9000 Virginia Manor Road, Suite 200, Beltsville, United States

INEEDMONEY87 Jul. 30 at 7:41 PM

$NXTC called that bear trap LFG

0 · Reply

CatHerder69 Jul. 30 at 6:57 PM

$NXTC Squeeze list

0 · Reply

INEEDMONEY87 Jul. 30 at 6:56 PM

$NXTC the break of 5 is quite concerning tho

0 · Reply

INEEDMONEY87 Jul. 30 at 6:55 PM

$NXTC idk i think hes just bear trapping, price comes right back up

0 · Reply

stockobserver Jul. 30 at 6:53 PM

$NXTC Definitely selling pressure now

0 · Reply

stockobserver Jul. 30 at 6:51 PM

$NXTC Pressure now. Hold the line

0 · Reply

INEEDMONEY87 Jul. 30 at 6:50 PM

$NXTC after buying a million shares he jsut rolls over....

0 · Reply

INEEDMONEY87 Jul. 30 at 4:58 PM

$NXTC 1.3 mil short this could get good if someone bigger comes along

0 · Reply

INEEDMONEY87 Jul. 30 at 3:47 PM

$NXTC cuttin up pretty easy here

0 · Reply

INEEDMONEY87 Jul. 30 at 3:38 PM

$NXTC its some bear whos short trying to cover cheap and not doing his homework...

0 · Reply

Latest News on NXTC

NextCure trading resumes

2026-07-16T14:45:56.000Z - 14 days ago

NextCure trading resumes

NextCure trading halted, volatility trading pause

2026-07-16T14:40:39.000Z - 14 days ago

NextCure trading halted, volatility trading pause

Why Is Penny Stock NextCure (NXTC) Up Today?

2026-07-14T12:26:44.000Z - 16 days ago

Why Is Penny Stock NextCure (NXTC) Up Today?

NextCure, Avere Therapeutics enter definitive merger agreement

2026-07-14T10:05:31.000Z - 16 days ago

NextCure, Avere Therapeutics enter definitive merger agreement

NextCure, Avere Therapeutics enter definitive merger agreement

2026-07-14T10:05:13.000Z - 16 days ago

NextCure, Avere Therapeutics enter definitive merger agreement

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

Jul 14, 2026, 6:00 AM EDT - 16 days ago

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

NextCure Slides: Corporate presentation

Jul 1, 2026, 8:00 AM EDT - 4 weeks ago

NextCure Slides: Corporate presentation

NextCure Transcript: AGM 2026

Jun 18, 2026, 11:00 AM EDT - 6 weeks ago

NextCure Transcript: AGM 2026

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

Jun 4, 2026, 8:00 AM EDT - 2 months ago

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

NextCure Transcript: KOL event

Jun 2, 2026, 8:00 AM EDT - 2 months ago

NextCure Transcript: KOL event

NextCure Press release: KOL event

Jun 2, 2026, 8:00 AM EDT - 2 months ago

NextCure Press release: KOL event

NextCure Slides: KOL event

Jun 2, 2026, 8:00 AM EDT - 2 months ago

NextCure Slides: KOL event

NextCure share weakness overdone, says Lucid Capital

2026-06-02T10:10:04.000Z - 2 months ago

NextCure share weakness overdone, says Lucid Capital

NextCure presents Phase 1 data for SIM0505 in gynecologic cancers

2026-06-01T13:49:45.000Z - 2 months ago

NextCure presents Phase 1 data for SIM0505 in gynecologic cancers

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

Jun 1, 2026, 8:00 AM EDT - 2 months ago

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

NextCure initiated with a Buy at Lucid Capital

2026-05-11T12:05:03.000Z - 2 months ago

NextCure initiated with a Buy at Lucid Capital

NextCure reports Q1 EPS ($1.87), consensus ($2.03)

2026-05-07T22:46:09.000Z - 2 months ago

NextCure reports Q1 EPS ($1.87), consensus ($2.03)

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 4:05 PM EDT - 3 months ago

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

NextCure Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

NextCure Quarterly report: Q1 2026

NextCure Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

NextCure Earnings release: Q1 2026

NextCure Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 3 months ago

NextCure Slides: Corporate presentation

NextCure initiates dose optimization portion of SIM0505 study

2026-05-04T12:10:48.000Z - 3 months ago

NextCure initiates dose optimization portion of SIM0505 study

NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

May 4, 2026, 7:05 AM EDT - 3 months ago

NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

NextCure Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

NextCure Proxy statement: Proxy filing

NextCure Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

NextCure Proxy statement: Proxy filing

NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

Apr 21, 2026, 10:15 AM EDT - 3 months ago

NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

NextCure granted Fast Track Designation for SIM0505 by FDA

2026-04-07T14:31:45.000Z - 4 months ago

NextCure granted Fast Track Designation for SIM0505 by FDA

NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

Apr 7, 2026, 8:05 AM EDT - 4 months ago

NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

Mar 31, 2026, 4:05 PM EDT - 4 months ago

NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

NextCure Provides Business Update and Reports Full Year 2025 Financial Results

Mar 5, 2026, 4:05 PM EST - 5 months ago

NextCure Provides Business Update and Reports Full Year 2025 Financial Results

NextCure Annual report: Q4 2025

Mar 5, 2026, 4:00 PM EST - 5 months ago

NextCure Annual report: Q4 2025

NextCure Earnings release: Q4 2025

Mar 5, 2026, 4:00 PM EST - 5 months ago

NextCure Earnings release: Q4 2025

NextCure trading resumes

2026-03-02T14:55:36.000Z - 5 months ago

NextCure trading resumes

NextCure trading halted, volatility trading pause

2026-03-02T14:45:08.000Z - 5 months ago

NextCure trading halted, volatility trading pause

NextCure expects SIM0505 Phase 1 dose escalation data update in Q2

2026-01-23T12:05:31.000Z - 6 months ago

NextCure expects SIM0505 Phase 1 dose escalation data update in Q2

NextCure Provides Business Update

Jan 23, 2026, 7:00 AM EST - 6 months ago

NextCure Provides Business Update

NextCure Slides: Corporate presentation

Jan 21, 2026, 7:00 AM EST - 6 months ago

NextCure Slides: Corporate presentation

NextCure Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 11:00 AM EST - 8 months ago

NextCure Transcript: Piper Sandler 37th Annual Healthcare Conference

NextCure files to sell 2.52M shares of common stock for holders

2025-11-26T21:05:41.000Z - 8 months ago

NextCure files to sell 2.52M shares of common stock for holders

NextCure Registration statement: Registration Filing

Nov 26, 2025, 7:00 AM EST - 8 months ago

NextCure Registration statement: Registration Filing

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 8:00 AM EST - 9 months ago

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

NextCure announces closing of $21.5M PIPE financing

2025-11-17T13:16:03.000Z - 9 months ago

NextCure announces closing of $21.5M PIPE financing

NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

Nov 17, 2025, 8:00 AM EST - 9 months ago

NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

NextCure prices 2.5M shares at $8.52 in private placement

2025-11-12T13:25:47.000Z - 9 months ago

NextCure prices 2.5M shares at $8.52 in private placement

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

Nov 12, 2025, 8:00 AM EST - 9 months ago

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

NextCure upgraded to Buy from Neutral at Ladenburg

2025-11-07T12:25:44.000Z - 9 months ago

NextCure upgraded to Buy from Neutral at Ladenburg

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 9 months ago

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

NextCure Quarterly report: Q3 2025

Nov 5, 2025, 4:00 PM EST - 9 months ago

NextCure Quarterly report: Q3 2025

NextCure Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 9 months ago

NextCure Earnings release: Q3 2025

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

Oct 16, 2025, 8:05 AM EDT - 10 months ago

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

NextCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:00 PM EDT - 11 months ago

NextCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:00 AM EDT - 11 months ago

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

NextCure Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

NextCure Quarterly report: Q2 2025

NextCure Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

NextCure Earnings release: Q2 2025

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Jul 24, 2025, 4:05 PM EDT - 1 year ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure Registration statement: Registration Filing

Jul 18, 2025, 8:00 AM EDT - 1 year ago

NextCure Registration statement: Registration Filing

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

Jun 16, 2025, 10:03 AM EDT - 1 year ago

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

Jun 16, 2025, 7:05 AM EDT - 1 year ago

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

May 29, 2025, 4:05 PM EDT - 1 year ago

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NextCure Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

NextCure Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

NextCure Quarterly report: Q1 2025

May 1, 2025, 4:00 PM EDT - 1 year ago

NextCure Quarterly report: Q1 2025

NextCure Earnings release: Q1 2025

May 1, 2025, 4:00 PM EDT - 1 year ago

NextCure Earnings release: Q1 2025

NextCure Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

NextCure Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

NextCure Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

NextCure Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 10, 2025, 8:45 AM EDT - 1 year ago

NextCure Transcript: 24th Annual Needham Virtual Healthcare Conference

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 7:00 AM EDT - 1 year ago

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Mar 6, 2025, 4:05 PM EST - 1 year ago

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

NextCure Earnings release: Q4 2024

Mar 6, 2025, 4:00 PM EST - 1 year ago

NextCure Earnings release: Q4 2024

NextCure Annual report: Q4 2024

Mar 6, 2025, 4:00 PM EST - 1 year ago

NextCure Annual report: Q4 2024

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

Jan 10, 2025, 8:05 AM EST - 1 year ago

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

NextCure Announces Acceptance of IND Application for LNCB74

Dec 10, 2024, 8:05 AM EST - 1 year ago

NextCure Announces Acceptance of IND Application for LNCB74

NextCure Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 5, 2024, 12:00 PM EST - 1 year ago

NextCure Transcript: Piper Sandler 36th Annual Healthcare Conference

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Nov 19, 2024, 8:05 AM EST - 1 year ago

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 4:05 PM EST - 1 year ago

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

NextCure Earnings release: Q3 2024

Nov 7, 2024, 3:00 PM EST - 1 year ago

NextCure Earnings release: Q3 2024

NextCure Quarterly report: Q3 2024

Nov 7, 2024, 3:00 PM EST - 1 year ago

NextCure Quarterly report: Q3 2024

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

Nov 5, 2024, 4:05 PM EST - 1 year ago

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

Sep 16, 2024, 8:05 AM EDT - 2 years ago

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

NextCure Quarterly report: Q2 2024

Aug 1, 2024, 4:00 PM EDT - 2 years ago

NextCure Quarterly report: Q2 2024

NextCure Earnings release: Q2 2024

Aug 1, 2024, 4:00 PM EDT - 2 years ago

NextCure Earnings release: Q2 2024

NextCure Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 27, 2024, 7:00 AM EDT - 2 years ago

NextCure Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 20, 2024, 4:10 PM EDT - 2 years ago

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

May 30, 2024, 4:05 PM EDT - 2 years ago

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

NextCure Quarterly report: Q1 2024

May 2, 2024, 4:00 PM EDT - 2 years ago

NextCure Quarterly report: Q1 2024

NextCure Earnings release: Q1 2024

May 2, 2024, 4:00 PM EDT - 2 years ago

NextCure Earnings release: Q1 2024

NextCure Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

NextCure Proxy statement: Proxy Filing

NextCure Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

NextCure Proxy statement: Proxy Filing

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Apr 24, 2024, 4:05 PM EDT - 2 years ago

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

NextCure Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

NextCure Proxy statement: Proxy Filing

NextCure Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 11, 2024, 12:45 PM EDT - 2 years ago

NextCure Transcript: 23rd Annual Needham Virtual Healthcare Conference

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Apr 8, 2024, 7:00 AM EDT - 2 years ago

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Apr 4, 2024, 7:05 AM EDT - 2 years ago

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 7:00 AM EDT - 2 years ago

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 8:55 AM EDT - 2 years ago

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

NextCure Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

NextCure Earnings release: Q4 2023

NextCure Annual report: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

NextCure Annual report: Q4 2023

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Mar 5, 2024, 8:05 AM EST - 2 years ago

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Jan 18, 2024, 4:05 PM EST - 2 years ago

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Dec 21, 2023, 7:05 AM EST - 2 years ago

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

NextCure Provides Year-End Clinical Pipeline Updates

Dec 14, 2023, 6:45 AM EST - 2 years ago

NextCure Provides Year-End Clinical Pipeline Updates

NextCure Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 30, 2023, 1:30 PM EST - 2 years ago

NextCure Transcript: Piper Sandler 35th Annual Healthcare Conference

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 7:00 AM EST - 2 years ago

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

Nov 15, 2023, 4:05 PM EST - 2 years ago

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure Quarterly report: Q3 2023

Nov 2, 2023, 5:00 PM EDT - 2 years ago

NextCure Quarterly report: Q3 2023

NextCure Earnings release: Q3 2023

Nov 2, 2023, 5:00 PM EDT - 2 years ago

NextCure Earnings release: Q3 2023

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 2, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

Oct 17, 2023, 8:05 AM EDT - 3 years ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

INEEDMONEY87 Jul. 30 at 7:41 PM

$NXTC called that bear trap LFG

0 · Reply

CatHerder69 Jul. 30 at 6:57 PM

$NXTC Squeeze list

0 · Reply

INEEDMONEY87 Jul. 30 at 6:56 PM

$NXTC the break of 5 is quite concerning tho

0 · Reply

INEEDMONEY87 Jul. 30 at 6:55 PM

$NXTC idk i think hes just bear trapping, price comes right back up

0 · Reply

stockobserver Jul. 30 at 6:53 PM

$NXTC Definitely selling pressure now

0 · Reply

stockobserver Jul. 30 at 6:51 PM

$NXTC Pressure now. Hold the line

0 · Reply

INEEDMONEY87 Jul. 30 at 6:50 PM

$NXTC after buying a million shares he jsut rolls over....

0 · Reply

INEEDMONEY87 Jul. 30 at 4:58 PM

$NXTC 1.3 mil short this could get good if someone bigger comes along

0 · Reply

INEEDMONEY87 Jul. 30 at 3:47 PM

$NXTC cuttin up pretty easy here

0 · Reply

INEEDMONEY87 Jul. 30 at 3:38 PM

$NXTC its some bear whos short trying to cover cheap and not doing his homework...

0 · Reply

stockobserver Jul. 30 at 3:32 PM

$NXTC Accumulation continues

0 · Reply

INEEDMONEY87 Jul. 30 at 2:50 PM

$NXTC no one notice that confident 20k purchase

0 · Reply

INEEDMONEY87 Jul. 30 at 2:47 PM

$NXTC insiders buying at $5 dumbies its not going lower

0 · Reply

INEEDMONEY87 Jul. 30 at 12:00 PM

$NXTC who ever is hammering the bid didnt do thier reading....

0 · Reply

INEEDMONEY87 Jul. 30 at 3:15 AM

$NXTC but the form 3 and 4 s are promising...

0 · Reply

INEEDMONEY87 Jul. 29 at 9:07 PM

$NXTC well not holding up there anymore, but still holding..

0 · Reply

INEEDMONEY87 Jul. 29 at 7:54 PM

$NXTC looks like were holding a fib 61.8 retract, ill be holding unless we really start breaking down

0 · Reply

stockobserver Jul. 29 at 5:03 PM

$NXTC 5.75 was tested 3 times the last few days

0 · Reply

INEEDMONEY87 Jul. 29 at 3:57 PM

$NXTC gota cover at some point or this is going big dark pool...

0 · Reply

INEEDMONEY87 Jul. 29 at 3:56 PM

$NXTC its just trapping a few more bears

0 · Reply

stockobserver Jul. 29 at 3:38 PM

$NXTC 5.75 is the point it can’t break

0 · Reply

INEEDMONEY87 Jul. 29 at 3:15 PM

$NXTC slowest snail rocket ever....

0 · Reply